Phase I Clinical Intramuscular Gene Transfer of rAAV1.CMV.huFollistatin344 Trial to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis
Phase of Trial: Phase I/II
Latest Information Update: 27 Nov 2017
Price : $35 *
At a glance
- Drugs AAV1 FS344 (Primary)
- Indications Duchenne muscular dystrophy; Inclusion body myositis
- Focus Adverse reactions
- 21 Nov 2017 Status changed from active, no longer recruiting to completed.
- 26 Jan 2016 Planned End Date changed from 1 Dec 2016 to 1 Jul 2017 as reported by ClinicalTrials.gov record.
- 26 Jan 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Jul 2017 as reported by ClinicalTrials.gov record.